Table 1.
Age, body weight at enrolment and treatment courses during first trimester including IPTp with SP
| Exposure group | |||||
|---|---|---|---|---|---|
| AL, N=150 | AL * and SP † , N=9 | SP † and/or quinine, N=135 | No anti-malarial, N=667 | Unknown anti-malarial, N=40 | |
| Age group, n (%) | |||||
| <20 years | 20 (13.3) | 1 (11.1) | 14 (10.4) | 118 (17.7) | 7 (17.5) |
| 20-24 years | 56 (37.3) | 5 (55.6) | 41 (30.4) | 204 (30.6) | 12 (30.0) |
| 25-29 years | 35 (23.3) | 2 (22.2) | 44 (32.6) | 199 (29.8) | 12 (30.0) |
| 30-39 years | 36 (24.0) | 1 (11.1) | 35 (25.9) | 139 (20.8) | 9 (22.5) |
| >40 years | 3 (2.0) | 0 (0) | 1 (0.7) | 7 (1.1) | 0 (0) |
| Body weight (kg) | |||||
| Mean (± SD) | 61.2 (±9.8) | 60.3 (±10.1) | 60.8 (±10.0) | 60.3 (±10.1) | 60.8 (±10.0) |
| Median | 60.0 | 59.0 | 60.0 | 59.0 | 59.7 |
AL = artemether-lumefantrine; SP = sulphadoxine-pyrimethamine.
*AL treatment in first trimester; †SP treatment in first trimester.
Exposure groups represent the treatment given to the pregnant woman for the malaria episode that had occurred most recently prior to enrolment (= index episode).